Summit Therapeutics Inc.SMMTNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-142.25M
↓ 206% below average
Average (9y)
$-46.49M
Historical baseline
Range
High:$15.07M
Low:$-142.25M
CAGR
+21.5%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-142.25M | -85.0% |
| 2023 | $-76.89M | -82.2% |
| 2022 | $-42.21M | +42.1% |
| 2021 | $-72.89M | -50.2% |
| 2020 | $-48.53M | -206.6% |
| 2019 | $-15.83M | +55.2% |
| 2018 | $-35.31M | -64.5% |
| 2017 | $-21.47M | -242.5% |
| 2016 | $15.07M | +161.3% |
| 2015 | $-24.56M | - |